REFERENCES
- Mochizuki M, Akduman L, Nussenblatt RB. Behçet’s disease. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St Louis, MO: Mosby; 1996:663–675.
- Evereklioglu C. Current concepts in the etiology and treatment of Behçet’s disease. Surv Ophthalmol. 2005;50:297–350.
- Namba K, Goto H, Kaburaki T, et al. A major review: current aspects of ocular Behçet’s disease in Japan. Ocul Immunol Inflamm. 2015;23:S1–23.
- Takeuchi M, Hokama H, Tsukahara R, et al. Risk and prognostic factors of poor visual outcome in Behçet’s disease with ocular involvement. Graefe’s Arch Clin Exp Ophthalmol. 2005;243:1147–1152.
- Kaburaki T, Araki F, Takamoto M, et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefe’s Arch Clin Exp Ophthalmol. 2010;248:709–714.
- George RK, Chan CC, Whitcup SM, et al. Ocular immunopathology of Behçet’s disease. Surv Ophthalmol. 1997;42:157–162.
- Atmaca LS. Fundus changes associated with Behcet’s disease. Graefe’s Arch Clin Exp Ophthalmol. 1989;227:340–344.
- Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362–1368.
- Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease. Arthritis Rheum. 2005;52:2478–2484.
- Abu El-Asrar AM, Abboud EB, Aldibhi H, et al. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int Ophthalmol. 2005;26:83–92.
- Accorinti M, Pirraglia MP, Paroli MP, et al. Infliximab treatment for ocular and extraocular manifestations of Behçet’s disease. Jpn J Ophthalmol. 2007;51:191–196.
- Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284–288.
- Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behçet’s disease. Arch Ophthalmol. 2012;130:592–598.
- Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884.
- Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behçet’s disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245–1250.
- Keino H, Okada AA, Watanabe T, et al. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye. 2014;28:1100–1106.
- Kaburaki K, Namba K, Sonoda KH, et al. Behçet’s disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol. 2014;58:120–130.
- Mizushima Y. The revised criteria and manual of treatments of Behcet’s disease. In: Report of Behcet’s Disease Research Committee, Ministry of Health and Welfare of Japan, Tokyo, 1987;16–17.
- International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
- Jabs DA, Nussenblatt RB, Rosenbaum JT. The Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
- Ozdal PC, Ortaç S, Taskintuna I, et al. Central retinal artery occlusion associated with ocular Behçet’s disease. Eur J Ophthalmol. 2002;12:328–330.
- Cassoux N, Fardeau C, Lehoang P. Ocular manifestations of Behçet’s disease. Ann Med Interne. 1999;150:529–534.
- Demiroğlu H, Barişta I, Dündar S, et al. Risk factor assessment and prognosis of eye involvement in Behcet’s disease in Turkey. Ophthalmology. 1997;104:701–705.